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Cholesterol-labeled oligonucleotides were found several years ago to inhibit HIV-1 in tissue culture at nanomolar concentrations. We
present evidence that this is mainly due to an electrostatic interaction between polyanionic oligonucleotide concentrated at the cell surface
and a positively charged region in the V3 loop of the HIV-1 envelope protein. When added to tissue culture, cholesterol-labeled
oligonucleotides became concentrated at the plasma membrane and potently inhibited virus entry and cell fusion mediated by the envelope
protein of some X4 strains of HIV-1, but had little effect on fusion mediated by R5 strains of HIV-1, amphotropic MLV envelope protein, or
VSV-G protein. Noncholesterol-labeled oligonucleotides did not bind to the cell surface or inhibit fusion. The pattern of susceptibility to
cholesterol-labeled oligonucleotides among HIV-1 strains was the same as reported for nonmembrane-associating polyanions such as dextran
sulfate, but the cholesterol-labeled oligonucleotides were effective at lower concentrations. Substitution of a basic 33 amino acid V3 loop
sequence from the envelope protein of a resistant strain into a susceptible strain made the envelope protein resistant to inhibition. Inhibition
by cholesterol-labeled oligonucleotides was abrogated by the polycation DEAE-dextran. Cholesterol-labeled oligonucleotides bound to
nonraft regions of the plasma membrane and did not inhibit HIV virus binding to cells. Many infectious agents first associate with target cells
via relatively nonspecific charge interactions; our data suggest that molecules that combine a membrane-targeting motif with multiple
negative charges might be useful to modify these interactions.
Published by Elsevier Inc.
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Cholesterol labeling of oligonucleotides was investigated
more than a decade ago as a strategy for increasing cellular
uptake of anti-sense oligonucleotides targeting various HIV-
1 genes. The covalent attachment of cholesterol caused
oligonucleotides to bind cell membranes, but contrary to
expectation, cholesterol-labeled oligonucleotides with
sequences unrelated to HIV-1 were equally potent inhibitors
(Agarwal et al., 1989; Farooqui et al., 1991; Krieg et al.,
1993; Stein et al., 1991). The most potent cholesterol-0042-6822/$ - see front matter. Published by Elsevier Inc.
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E-mail address: jsilver@nih.gov (J. Silver).labeled oligonucleotides inhibited HIV-1 infection by 50%
at concentrations approximately 10 nM. Further studies
showed that cholesterol-labeled oligonucleotides inhibited
HIV-1 entry, syncytium formation, and reverse transcriptase
activity (Stein et al., 1991).
About the same time, a variety of polyanionic com-
pounds was found to inhibit HIV-1 (Baba et al., 1988; Ito et
al., 1987; McClure et al., 1992; Mitsuya et al., 1988;
Ohshiro et al., 1996; Patel et al., 1993; Rodriguez et al.,
1995; Schols et al., 1990). These compounds include
synthetic products like dextran sulfate and heparin, and
natural analogues such as chondroitin sulfate, heparan
sulfate, and other proteoglycans. Some of the natural
compounds are concentrated at the cell surface, where they
may provide binding sites for HIV-1 (Ibrahim et al., 1999;
Mondor et al., 1998; Ohshiro et al., 1996; Patel et al., 1993;
Saphire et al., 1999) and other viruses (Chen et al., 1997;004) 50–61
Fig. 1. Flow cytometry analysis of CEM cells incubated with fluorescently
labeled oligonucleotide. y-axis, number of cells. x-axis, fluorescence
intensity. (A) Cholesterol enhances oligonucleotide binding to cells. Cells
were incubated with 0.25 AM cholesterol-labeled beta actin oligonucleotide
without fluor as negative control (red line), with 0.25 AM fluorescein-
labeled circularly permuted version of the beta actin oligonucleotide (blue
line), or with 0.25 AM fluorescein-plus-cholesterol-labeled beta actin
oligonucleotide (green line). (B) Cells incubated with increasing concen-
trations of fluorescein-plus-cholesterol-labeled beta actin oligonucleotide.
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1995; Summerford and Samulski, 1998; Wudunn and Spear,
1989). The polyanionic nature of these compounds imme-
diately suggested that they might be interacting with
positively charged regions in target proteins. In the case of
HIV-1, the crystal structure of the envelope SU protein
(Kwong et al., 1998) shows a cluster of positive charges on
a face of the SU envelope that becomes exposed after
binding to CD4 (Rizzuto et al., 1998) and in a 33 amino acid
disulfide-linked loop involved in co-receptor specificity
(Chung et al., 1998; Cocchi et al., 1996; Hoffman and
Doms, 1999; Hoffman et al., 1999). The latter region, the
V3 loop, is highly variable between HIV strains, including
variability in the number of basic residues (Berger et al.,
1997; Fouchier et al., 1992). It was found that the most basic
V3 loops, which tend to be in strains that use the CXCR4
co-receptor and grow well in T-cell lines, interact most
strongly with polyanions, consistent with a predominantly
electrostatic interaction (Callahan et al., 1991; Demaria and
Bushkin, 1996; Harrop et al., 1994; Moulard et al., 2000;
Rodriguez et al., 1995; Zhang et al., 2002).
Since DNA is a polyanion, we hypothesized that
cholesterol-labeled oligonucleotides might inhibit HIV-1
via charge interactions, with the cholesterol moiety enhanc-
ing potency by targeting oligonucleotide to the cell surface.
To test this hypothesis, we quantified cell surface choles-
terol–oligonucleotide binding using flow cytometry and
confocal microscopy. We compared the inhibitory effect of
cholesterol–oligonucleotides on fusion mediated by strains
of HIV differing in co-receptor usage and V3 loop charge.
We tested whether the inhibition was sensitive to a
polycation, DEAE-dextran. Our results support the hypoth-
esis and suggest that the combination of membrane targeting
and polyanionicity could be important for drugs altering cell
surface interactions of several pathogens.(C) Complementary oligonucleotide enhances binding. Cells were incu-
bated with 0.25 AM fluorescein-plus-cholesterol-labeled beta actin oligo-
nucleotide with (+, red) or without (, green) 0.25 AM complementary,
noncholesterol-labeled oligonucleotide. (For interpretation of the references
to colour in this figure legend, the reader is referred to the web version of
this article.)Results
Binding of cholesterol-labeled oligonucleotides to cells
We began with a 25-mer oligonucleotide derived from a
portion of the beta actin gene labeled at the 3V end with
cholesterol and the 5Vend with fluorescein. This sequence
was chosen because it was previously shown that the ability
to inhibit HIV-1 does not require HIV-1-related sequence,
and we had a variety of fluor-labeled versions of this
oligonucleotide that could be used as controls. The
cholesterol-plus-fluorescein-labeled oligonucleotide bound
to CEM cells whereas fluor-labeled oligonucleotides with-
out cholesterol did not (Fig. 1A). The amount of cholesterol-
labeled oligonucleotide that bound to cells increased with
increasing concentration (Fig. 1B). Comparing the fluores-
cence intensity of cells shown in Fig. 1B with the
fluorescence intensity of commercially available beads
containing known amounts of fluorescein (rainbow calibra-tion particles, Spherotech, Libertyville, IL), we estimated
that CEM cells bound approximately 2  104 molecules of
fluorescein-plus-cholesterol-labeled oligonucleotide per cell
when labeled with 0.25 AM oligonucleotide, and approx-
imately 2  105 molecules/cell when labeled with 2.5 AM
oligonucleotide. This represents about a 100-fold increase in
concentration at the cell surface compared to bulk solution,
assuming the CEM cells have a diameter of 10 Am and the
oligonucleotide has a length of 4 nm.
Unexpectedly, we found that the mean fluorescein
fluorescence per cell increased about 5-fold when comple-
mentary, Cy5-labeled oligonucleotide (without a cholesterol
tag) was included in the labeling mixture (Fig. 1C). The
increased fluorescein fluorescence is likely due to increased
K.-S. Ahn et al. / Virology 330 (2004) 50–6152binding efficiency of the cholesterol-labeled oligonucleotide
when in a double-strand configuration. We considered an
alternative possibility that addition of complementary
oligonucleotide might increase fluorescence by reducing
quenching, which might result from breaking up weak
interactions between densely packed, single-stranded oligo-
nucleotides on the cell surface. However, this possibility
seems unlikely because the complementary oligonucleotide
did not increase fluorescein fluorescence when it was added
after the fluorescein–cholesterol-labeled oligonucleotide had
bound to cells and excess fluorescein–cholesterol–oligonu-
cleotide was washed away. In this experiment, binding of
the complementary, noncholesterol-labeled oligonucleotide
was confirmed by virtue of its Cy-5 red fluorescence (data
not shown). Thus, this experiment also shows that single-
stranded, cholesterol-labeled oligonucleotide on a cell sur-
face remains in a conformation capable of binding
complementary oligonucleotide.
We next investigated the stability of cholesterol–oligonu-
cleotide bound to cells. After incubating in 0.25 AM
cholesterol–oligonucleotide for 15 min, cells were washed,
fixed or left unfixed, incubated at 4 or 37 8C, and analyzed by
flow cytometry at various times thereafter. The mean
fluorescence of cells that had bound fluorescent, choles-
terol-labeled oligonucleotide decreased 4- to 10-fold over 60
minwhen the cells were incubated at 37 8C (Fig. 2, right side),
compared to less than 2-fold when cells were kept on ice (Fig.
2, left side) or fixed with paraformaldehyde. The loss of
fluorescence at 37 8C could result from endocytosis with
degradation or quenching of intracellular fluor, or enzymatic
degradation of oligonucleotide on the cell surface. This rate
of loss probably does not impact the amount of cell surface
cholesterol–oligonucleotide in experiments assaying the
effect of such oligonucleotides on virus-mediated fusion
(see below), because in such experiments we typically
incubated approximately 105 cells overnight in 1 ml of 0.25Fig. 2. Loss of fluorescence with time of CEM.NRK-CCR5-Luc cells
incubated with 2.5 AM (open symbols) or 0.25 AM fluorescein-plus-
cholesterol-labeled beta actin oligonucleotide (closed symbols). After 15-
min incubation on ice, cells were washed and fixed with 1% paraformalde-
hyde (squares) or left unfixed (triangles). Flow cytometry was performed on
aliquots of cells at time 0, after 30 min, and after 60 min at 4 8C (left side of
figure). Remaining cells were then warmed to 37 8C and mean fluorescence
measured after 1 h at 37 8C (2 h time point). y-axis, geometric mean
fluorescence intensity.AM cholesterol–oligonucleotide, which corresponds to
approximately 109 cholesterol–oligonucleotide molecules/
cell, a 10,000-fold excess over the amount of cholesterol–
oligonucleotide that bound to the surface of cells at one time.
If the half-life of surface cholesterol–oligonucleotide is 15
min, only approximately 107 cholesterol–oligonucleotide
molecules would be consumed per cell after 24 h of culture.
As a complement to flow cytometry, we used confocal
microscopy to examine the binding of cholesterol-labeled
oligonucleotides to cells. When CEM cells were incubated
with 250 nM fluorescein-plus-cholesterol-labeled oligonu-
cleotide for 15 min at 4 8C and then washed, the
oligonucleotide was easily detected on the surface of
healthy cells (arrows, Figs. 3A and B). Noncholesterol-
labeled oligonucleotide did not stick to live cells under the
same conditions (arrows, Figs. 3C and D). When comple-
mentary oligonucleotides were added together, one labeled
with cholesterol plus fluorescein, the other with Cy5 alone,
the noncholesterol-labeled oligonucleotide now bound to
the cell surface (Fig. 3F); presumably, this is due to duplex
formation with the cholesterol-labeled complementary
oligonucleotide on the cell surface. Binding of the choles-
terol-labeled oligonucleotide was also enhanced in the
presence of its complement (compare Figs. 3E and B). In
addition, small amounts of fluorescent oligonucleotide
could be seen inside cells (Figs. 3E and F), presumably a
result of endocytosis. All of these results corroborate the
flow cytometry observations.
Fluorescence microscopy revealed one new feature: dead
cells (labeled bdQ, Figs. 3A–D) took up large amounts of
fluor-labeled oligonucleotide, independent of cholesterol
labeling. The fields shown in Fig. 3 were chosen to illustrate
this phenomenon. Such very bright cells did not influence
the flow cytometry results because dead cells were a minor
population and were bgated outQ of the flow cytometry
analyses. We do not know the reason for the enhanced
staining of dead cells by fluorescent oligonucleotides, but
this phenomenon suggests the importance of using healthy
cultures (or being able to disregard dead cells) in experi-
ments in which the extent of binding of cholesterol-labeled
oligonucleotide is an important variable.
The same pattern of binding of cholesterol-labeled
oligonucleotide and nonbinding of noncholesterol-labeled
oligonucleotide, unless its complement was bound or cells
were dead, was seen by fluorescence microscopy with
oligonucleotides labeled with Cy5 or fluorescein at the 3Vor
5V ends and cholesterol at the 5V end. Similar results were
obtained with 1G5 Jurkat lymphocytes and with NIH3T3,
HeLa, and HEK293 cells attached to tissue culture plates or
in suspension.
Inhibition of HIV-1 entry and cell fusion
We first measured the effect of cholesterol-labeled
oligonucleotide on HIV-1 entry using single-round infec-
tion with a luciferase-encoding vector pseudotyped with
Fig. 3. Immunofluorescence of CEM.NRK-CCR5-Luc cells incubated with a fluorescein- and cholesterol-labeled beta actin oligonucleotide or a
complementary, Cy-5-labeled oligonucleotide lacking cholesterol. The structures of the oligonucleotides used in each experiment are shown below. (A and B)
Transmitted light and fluorescein channel image of cells incubated with fluorescein-plus-cholesterol–oligonucleotide. (C and D) Transmitted light and Cy-5
channel image of cells incubated with Cy5-oligonucleotide lacking cholesterol. (E and F) Fluorescein (E) and Cy-5 (F) channel image of cells labeled with both
oligonucleotides. Arrows point to the same cell in upper and lower images. bdQ indicates dead cells that stain intensely with the fluorescent oligonucleotides.
Fluorescence detector settings were the same for B and E, and D and F.
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CXCR4CEM cells with vector pseudotyped by HIV-1
envelope protein derived from a T-cell tropic strain (NL4-
3) was inhibited over 700-fold by 250 nM cholesterol-
labeled beta actin oligonucleotide added at the time of
infection and left in the culture until assay 2 days later,
whereas the same vector pseudotyped by amphotropic
MLV envelope or VSV-G was inhibited less than 4-fold
(Fig. 4). The minimal inhibition of VSV-G and ampho-
tropic MLV pseudotypes argues that most of the inhibition
is unrelated to any effect on reverse transcriptase (Stein et
al., 1991), since all the vectors used the same reverseFig. 9. Triton X-100 solubility of cholesterol–oligonucleotide bound to cells.
oligonucleotide, 0.25 AM Cy-5-labeled complementary oligonucleotide, and 25 Ag/
with 0.5% Triton X-100 in PBS on ice for 5 min. (A–D) Before Triton X-100; (E–
(displayed in red); (C and G) FITC channel (displayed in green); (D and H) ovetranscription machinery in this assay, but one was inhibited
100 times more than the others.
To confirm that the inhibition of infection was not due
to inhibition of reverse transcriptase, we made use of a cell
fusion assay that does not involve reverse transcription in
which an HIV-1-LTR-driven lacZ reporter in U373-MAGI
cells is induced by fusion with cells expressing HIV-1 Env
and Tat. When co-cultivated with transfected HEK293
cells expressing HIV-1 NL4-3 Env and Tat, the U373-
MAGI-CXCR4CEM indicator cells formed numerous
lacZ-positive syncytia, whereas lacZ and syncytia were
not seen when the co-culture was performed in theHeLa TZM-bl cells were stained with 0.25 AM cholesterol-labeled actin
ml FITC-labeled cholera toxin B for 30 min on ice, washed, and then treated
F) after Triton X-100. (A and E) Transmitted light; (B and F) Cy5 channel
rlay of Cy5 and FITC images.
Fig. 4. Cholesterol–oligonucleotide inhibits infection by retroviral vector pseudotyped with HIV-1 NL4-3 Env. Luciferase enzyme activity (in relative light
units, RLU) of U373-MAGI-CXCR4CEM cells 2 days after infection with HIV-1 luciferase vectors pseudotyped by various envelope proteins, cultured in the
presence (open bars) or absence (hatched bars) of 0.25 AM cholesterol-labeled beta actin oligonucleotide.
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(Fig. 5). Activation of lacZ in this system is not due to
transfer of secreted Tat since the same vector with an R5-
tropic envelope did not induce lacZ, although it did
transfer Tat to indicator cells expressing CCR5 (see
below).
To see if cholesterol-labeled oligonucleotides inhibited
HIV-1 envelope protein-mediated fusion in lymphocytes,
we used 1G5 Jurkat indicator cells bearing CD4, CXCR4,
and an LTR-driven luciferase reporter. When these indicator
cells were co-cultured with HEK293 cells transiently
transfected to express HIV-1 NL4-3 Env and Tat, luciferase
activity increased from approximately 100 to 10,000–
100000 relative light units. Cholesterol-labeled beta actin
oligonucleotide inhibited the induction of luciferase mark-
edly at 250 nM, with an ID50 approximately 10 nM (Fig. 6).
At 250 nM, a noncholesterol-labeled oligonucleotide with
the same sequence neither inhibits luciferase induction, nor
did 2.5 AM cholesterol covalently attached to polyethylene
glycol. Cholesterol-polyethylene glycol was used as a
negative control because cholesterol was linked to the beta
actin oligonucleotide via a six carbon polyethylene glycol
spacer and polyethylene glycol enhances water solubility of
cholesterol. These controls show that both cholesterol and
oligonucleotide were necessary for inhibition. The 250-nM
dose of cholesterol-labeled oligonucleotide had no toxic
effect on the lymphocytes or HEK293 cells detected by lightFig. 5. Cholesterol–oligonucleotide inhibits cell fusion by cells expressing HIV-1
(A) or absence (B) of 0.25 AM cholesterol-labeled beta actin oligonucleotide, with
env and tat, and stained for lacZ 24 h after co-culture.microscopy, including no increase in the proportion of cells
staining with propidium iodide.
To test R5-tropic strains of HIV, we used a CD4-positive,
CEM lymphocyte indicator cell (CEM.NRK-CCR5-Luc) that
expresses both CXCR4 and CCR5 co-receptors, and fuses
with cells expressing X4 or R5-tropic envelope proteins.
When co-cultivated with HEK293 cells transfected with an
expression vector for Tat plus X4-tropic (NL4-3) Env or R5
tropic (AD8) Env, luciferase activity increased several
hundred fold. Cholesterol-labeled actin oligonucleotide
(250 nM) blocked the rise in luciferase induced by the X4
Env but not the R5 Env (Fig. 7A). The lack of inhibition of the
R5 Env-mediated fusion shows that the oligonucleotide was
not toxic.
Given the apparent correlation between susceptibility to
cholesterol-labeled oligonucleotide and use of the X4 co-
receptor, we tested whether cholesterol–oligonucleotides
downmodulated CXCR4 on the cell surface. Flow cytom-
etry showed that binding of fluorescently labeled mono-
clonal antibody to CXCR4 on CEM cells was unaffected by
the presence of single- or double-stranded, cholesterol-
labeled oligonucleotide (data not shown). Thus, cholesterol–
oligonucleotide inhibition of fusion mediated by X4-tropic
envelope was not due to downmodulation of the co-receptor.
The NL4-3 envelope protein has nine basic residues in its
V3 loop (two lysine, six arginine, one histidine) and no acidic
residues, for a net charge of +9 (assuming the histidine isNL4-3 Env. U373-MAGI-CXCR4CEM cells were cultured in the presence
HEK293 cells transiently transfected with a vector encoding HIV-1 NL4-3
Fig. 6. Dose dependence of cholesterol–oligonucleotide inhibition of cell fusion. Luciferase activity of 1G5 Jurkat indicator cells cultured with HEK293 cells
transiently transfected with a vector encoding HIV-1 NL4-3 env and tat. Cultures were done in the presence of increasing concentrations of cholesterol-labeled
beta actin oligonucleotide (lanes 4–7), or the same oligonucleotide lacking cholesterol at 250 nM (lane 2), or cholesterol-polyethylene glycol (without
oligonucleotide) at 2.5 AM (lane 3).
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(one lysine, four arginine, two histidine) and two acidic
residues, for a net charge of +5 (Table 1). To examine the
effect of charge differences in the V3 loop, we took advantage
of a chimeric envelope gene derived from T-tropic strain IIIB
with a 33 amino acid substitution of V3 loop sequences fromFig. 7. Env strain dependence of cholesterol–oligonucleotide inhibition of cell fusio
both CXCR4 and CCR5), incubated overnight with HEK293 cells transiently tran
presence (open bars) or absence (hatched bars) of 0.25 AM cholesterol-labeled b
TZM-bl, reporter was beta galactosidase, and cholesterol-labeled oligonucleotide
Results shown in panels A, B, and C are from single experiments and are represen
envelope strain.M-tropic strain JR-FL (Hwang et al., 1992). The JR-FL V3
loop is identical to AD8 except for a conservative substitution
of glutamic acid for aspartic acid (Table 1). The chimeric
envelope was R5 tropic (did not fuse with indicator cells
expressing CXC4 as the only co-receptor) and was not
inhibited by cholesterol–oligonucleotide (Fig. 7A). Equiv-n. (A) Luciferase activity of indicator CEM.NRK-CCR5-Luc cells (bearing
sfected with vectors encoding HIV-1 tat and various strains of env, in the
eta actin oligonucleotide. (B) Same as A except indicator cells were HeLa
concentration was 0.67 AM. (C) Same indicator cells and conditions as A.
tative of results obtained in two or more independent experiments with each
Table 1
Net charge, co-receptor usage, and V3 loop sequences of cholesterol-oligo-sensitive and resistant HIV-1 strains tested (arginine and lysine residues in bold;
histidines underlined; acidic residues in italics; period, same amino acid as 4-3; dash, deletion)
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fectedwith vectors encoding envelope proteins from pNL4-3,
IIIB, IIIB with the JR-FL V3 loop, and AD8, and then co-
cultured with HeLa TZM-bl indicator cells (which express
CXCR4 and CCR5) and tested for induction of beta-
galactosidase activity (Fig. 7B). These results show that the
V3 loop is a major determinant of susceptibility to inhibition
by cholesterol–oligonucleotides.
To see if the controlling property of the V3 loop was its
charge or its co-receptor affinity, we tested a native X4
envelope protein with a less basic V3 loop from strain
92UG021.6. This envelope protein has a V3 loop with net
charge of +5 (Table 1) and was not inhibited by cholesterol–
oligonucleotide (Fig. 7C). We confirmed that the 92UG021.6
envelope protein caused fusion with indicator cells express-Fig. 8. Reversal of cholesterol–oligonucleotide effect by DEAE-dextran. (A) Luci
with HEK293 cells transiently transfected with vector encoding HIV-1 NL4-3 env
cholesterol-labeled beta actin oligonucleotide with or without 20 Ag/ml DEAE-dext
fluorescein-plus-cholesterol-labeled beta actin oligonucleotide with (+, red) or with
to colour in this figure legend, the reader is referred to the web version of this aing CXCR4 as the only co-receptor (data not shown). Thus,
susceptibility to inhibition by cholesterol-labeled oligonu-
cleotide required a highly basic V3 loop in these experiments
regardless of whether the envelope protein used X4 or R5 as
a co-receptor.
To test the hypothesis that the interaction between
cholesterol–oligonucleotide and envelope is largely electro-
static, we asked whether a polycation would block the
inhibitory effect of cholesterol–oligonucleotides. DEAE-
dextran at 20 Ag/ml had little effect on the induction of
luciferase in the absence of cholesterol–oligonucleotide,
indicating lack of toxicity; however, it completely neutral-
ized the inhibitory effect of 250 nM cholesterol-labeled
oligonucleotide (Fig. 8A). DEAE-dextran is a polycation
that forms a charge-mediated complex with DNA, aferase activity of CEM.NRK-CCR5-Luc indicator cells incubated overnight
and tat in the presence (open bars) or absence (hatched bars) of 0.25 AM
ran. (B) Histogram of fluorescence intensity of cells incubated with 0.25 AM
out (, green) 20 Ag/ml DEAE-dextran. (For interpretation of the references
rticle.)
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(Thomas and Klibanov, 2003). To see if DEAE-dextran
affected binding of cholesterol-labeled oligonucleotide to
the cell surface, we examined CEM cells by flow cytometry.
Rather than inhibit binding, DEAE-dextran enhanced the
binding of cholesterol-labeled oligonucleotide, with mean
fluorescence increasing by about 5-fold in the presence of
DEAE-dextran (Fig. 8B). Confocal microscopy confirmed
increased binding in the presence of DEAE-dextran, but the
pattern of cell surface binding changed from uniform to
punctate (not shown). Thus, the reversal of the cholesterol–
oligonucleotide effect could be related to a change in the
manner in which it coats the cell surface.
Because cholesterol is enriched in specialized plasma
membrane regions termed rafts that have been implicated in
viral budding and fusion (Kozak et al., 2002; Manes et al.,
2000; Popik et al., 2002), we investigated whether
cholesterol–oligonucleotides localized to rafts. Raft lipids
and proteins have been operationally defined based on
resistance to extraction with low concentrations (approx-
imately 1%) of Triton X-100 at 4 8C. Therefore, we
compared the Triton X-100 extractability of a classical raft
lipid GM1, which binds cholera toxin B, to that of surface-
bound cholesterol–oligonucleotide. We stained HeLa-TZM-
bl cells with oligonucleotide duplex consisting of choles-
terol-labeled actin oligonucleotide plus Cy5-labeled com-
plementary oligonucleotide alone or in combination with
FITC-labeled cholera toxin B. The singly or doubly labeled
cells were then treated with 0.5% Triton X-100 in PBS at 4
8C for 5 min. Surprisingly, the Cy5 signal was completely
removed by Triton, while the FITC signal was stable (Fig. 9,
see page 53). To be sure that Triton treatment did not disrupt
the DNA duplex or quench the Cy5 fluorescence, we
labeled streptavidin-coated beads with a biotinylated version
of the actin oligonucleotide plus the Cy5-labeled comple-
mentary oligonucleotide. Triton treatment of these beads did
not reduce Cy5 fluorescence. Thus, the cholesterol–oligo-
nucleotide apparently preferentially labels nonraft regions of
the plasma membrane.
Finally, we investigated whether the cholesterol–oligo-
nucleotide inhibited binding of virus to cells. High concen-Table 2
Effect of heparin (10 Ag/ml), cholesterol-labeled, or noncholesterol-labeled
actin oligonucleotide (0.5 AM) on binding and infectivity of HIV virions to
HeLa-TZM-bl cells
Virus Polyanion p24
bound
(pg)
Percentage
of control
Number of
infectious
centers
Percentage
of control
HIV 4–3 none 107 100 1180 100
heparin 51 47 94 8
chol-oligo 88 82 11 1
plain oligo 88 82 670 57
HIV AD8 none 24 100 75 100
heparin 21 88 18 24
chol-oligo 34 143 69 92
plain oligo 33 139 55 73trations of polyanions inhibit CD4-independent binding of
HIV-1 to some cells based on weak electrostatic interaction
between positively charged virions and negatively charged
cell surface glycoseaminoglycans. Following a published
protocol (Mondor et al., 1998), we incubated HIV virions
with 5  105 HeLa-TZM-bl indicator cells in suspension at
37 8C for 30 min, then washed the cells and measured the
amount of cell-associated virus by p24 ELISA. Control
experiments showed that about 1% of the starting p24
bound to cells under these conditions, or about 1–5 virions
per cell assuming 1000 p24 molecules per virion. We
compared the effect of 0.5 AM cholesterol-labeled actin
oligonucleotide, the same oligonucleotide without choles-
terol, or 10 Ag/ml heparin. Heparin reduced binding of HIV
strain 4-3 virions approximately 2-fold, while it had no
effect on binding of strain AD8 virions, consistent with
binding being V3-loop charge related (Table 2). The
cholesterol–oligonucleotide and the unlabeled oligonucleo-
tide did not significantly inhibit binding of either virus. To
confirm that the cholesterol–oligonucleotide inhibited infec-
tion in this experimental protocol, one-tenth of each virus–
cell incubation mixture was plated in tissue culture medium
containing the same concentration of heparin, cholesterol–
oligonucleotide, or plain oligonucleotide. Virus infectivity
was measured by staining the cells for beta-galactosidase
activity 2 days later. Heparin inhibited HIV 4-3 infection 12-
fold, versus 4-fold for HIVAD8 (Table 2). The cholesterol–
oligonucleotide inhibited HIV 4-3 infection 100-fold and
had no appreciable effect on infection by HIV AD8. The
unlabeled oligonucleotide had little effect (b2-fold) on
either virus. The cholesterol–oligonucleotide therefore
strongly inhibits infection by HIV strain 4-3 without a
corresponding inhibition of binding.
Since the p24 binding assay does not distinguish between
binding of virus particles versus free p24 molecules, we first
purified virions by centrifugation for 90 min at 13500 rpm
in an Ependorf centrifuge. In the initial HIV 4-3 virus stock,
about 80% of the p24 was pelleted by one round of
centrifugation, and 99% of the resuspended pellet was
pelletable in a second centrifugation. The results in Table 2
were performed using the twice-pelleted virus preparation
and confirmed results obtained with unpelleted virus (not
shown). Thus, the p24 bound to the HeLa cells in this assay
reflects primarily binding of virions rather than free p24.Discussion
Our results are consistent with previous reports showing
that cholesterol labeling of oligonucleotides enhances their
binding to cells (Krieg et al., 1993) and that cholesterol-
labeled phosphorothioate oligonucleotides with apparently
arbitrary sequences inhibit HIV-1. These earlier HIV studies
showed some variability in inhibitory potency among
oligonucleotides with different sequences (Farooqui et al.,
1991). The most potent inhibitory oligonucleotides in these
K.-S. Ahn et al. / Virology 330 (2004) 50–6158studies, as in ours, had ID50’s approximately 10–50 nM,
which is only about 10-fold less potent than alpha-helical
peptides from the C-terminus of HIV TM that are now used
clinically to treat HIV-1 infection (Baldwin et al., 2003). Only
one strain of HIV-1 was tested in the early HIVexperiments,
the T-cell-tropic IIIB strain (Agarwal et al., 1989; Krieg et al.,
1993). The earlier experiments did not establish a mechanism
of inhibition beyond showing a block to fusion and to reverse
transcription in vitro (Krieg et al., 1993; Stein et al., 1991).
We show here that unlike the envelope proteins of T-cell-
tropic NL4-3 and IIIB, the envelope protein of the macro-
phage-tropic HIV-1 strain AD8 is resistant to inhibition by
cholesterol-labeled oligonucleotides, as is an X4-tropic
envelope from strain 92UG021.6 and a chimeric envelope
with V3-loop sequences from macrophage-tropic strain JR-
FL in a IIIB envelope backbone. The V3 loops of the
susceptible strains tested have 4–5 more net positive charges
than the V3 loops of the resistant envelopes. The highly
basic V3 loops of NL4-3 and IIIB were previously shown to
provide targets for inhibition by polyanionic glycosamino-
glycans (Schols et al., 1990; Zhang et al., 2002). Hence, our
results suggest a model in which cholesterol–oligonucleo-
tides concentrate at the cell surface and inhibit susceptible
HIV-1 strains via an electrostatic interaction between
negatively charged oligonucleotide and positively charged
envelope residues involving the V3 loop. Consistent with
this model, polycationic DEAE-dextran, which binds DNA
and would be expected to counteract its negative charge,
abolished the inhibitory effect.
Our finding that V3 loop sequences from some T cell-
tropic HIV-1 strains are important for cholesterol–oligonu-
ceotide inhibition does not mean that these residues, by
themselves, act as a target. They could form part of a larger
surface that, as a whole, binds polyanions (Moulard et al.,
2000). Consistent with this possibility, when we inserted the
V3 loop from NL4-3 into the ecotropic MLV envelope at a
site in SU that tolerates insertions (Kayman et al., 1999), the
modified ecotropic MLV envelope fused normally to its
receptor but was not susceptible to inhibition by cholesterol-
labeled oligonucleotides (data not shown); thus, the V3 loop
by itself is not sufficient for cholesterol–oligonucleotide
inhibition.
The local concentration of oligonucleotide on the surface
of cells incubated with cholesterol-labeled oligonucleotides
is probably high enough to inhibit HIV by acting as a
polyanion. From flow cytometry we estimate that the local
concentration of oligonucleotide at the surface of cells
incubated in 250 nM cholesterol–oligonucleotide (in bulk
solution) is about 25 AM. This is comparable to bulk
solution ID90 concentrations of dextran sulfate and heparin
with similar molecular weights (Baba et al., 1988). It is
therefore likely that noncholesterol-labeled oligonucleotide
would also inhibit fusion at 100-fold higher concentrations
than required by the cholesterol–oligonucleotide.
While we were surprised that the cholesterol–oligonucleo-
tide was Triton X-100 extractable, we note that cholesterol isenriched in, but not restricted to, raft regions. It may be that
the oligonucleotide moiety attached to cholesterol preferen-
tially targets the conjugate to nonraft regions. The fact that
cholera toxin B stainingwas not made Triton X extractable by
the presence of cholesterol–oligonucleotide implies that the
latter did not destabilize rafts. The simplest interpretation of
the data is that inhibition of fusion by cholesterol–oligonu-
cleotide is unrelated to rafts. Our data do not rule out the
contrary possibility that cholesterol–oligonucleotide inhibits
fusion by binding SU and drawing HIV to nonraft regions of
the plasma membrane.
The observation that cholesterol–oligonucleotide in-
hibited HIV 4-3 infection 100-fold without significantly
reducing virus binding in the p24 assay implies that the
cholesterol–oligonucleotide inhibits a post-attachment step in
the fusion process. Binding in the p24 assay is not dependent
on CD4 (Mondor et al., 1998). One possibility is that cell-
bound cholesterol–oligonucleotide binds positively charged
regions in virion SU, holding the virus in a way that prevents
interaction with CD4 or co-receptor, or conformational
changes that follow interaction with these molecules in the
fusion pathway.
Most cells have a surface coating of polyanionic glyco-
saminoglycans that are believed to play a role in many cell
surface phenomena such as binding and internalization of
basic peptides in cell signaling and entry of diverse pathogens
(Belting, 2003; Zhang et al., 2002). Cholesterol-labeled
oligonucleotides presumably modify this layer via electro-
static interactions or mimic it in cells lacking such surface
charges. It is therefore likely that cholesterol–oligonucleo-
tides can affect other cell surface phenomena involving
proteoglycans. Several features related to their composition
suggest potential advantages of cholesterol–oligonucleotides
to probe these interactions. When fluorescently labeled, they
should provide a marker for polyanion rich regions on the
plasma membrane. Their length, and hence extension from
the cell surface, is adjustable by design. Their secondary
structure is partially controllable with complementary oligo-
nucleotide, and this clearly affects membrane binding
properties (see Figs. 1C and 3). Cholesterol–oligonucleotides
could conceivably be used in combination with laser tweezers
to sense forces or to pull on the plasma membrane (Pralle et
al., 2000). If, as we propose, many of the interesting
properties of cholesterol–oligonucleotides result from the
combination of membrane tropism and charge, they might be
useful as models for drugs with similar structural features to
modify cell surface phenomena.Materials and methods
Reagents
Oligonucleotides were labeled during synthesis with
cholesterol, fluorescein, Cy-5, or biotin using 3V-CPG or
5Vphosphoramidite reagents with six carbon spacers from
K.-S. Ahn et al. / Virology 330 (2004) 50–61 59Glen Research (Sterling, VA). Following cleavage from the
column with ammonium hydroxide and deprotection for 4 h
at 50 8C, the oligonucleotides were dried, dissolved in
water, and purified by ethanol precipitation. Some oligonu-
cleotides were additionally purified by polyacrylamide gel
electrophoresis. Cholesterol-PEG and DEAE-dextran were
from Sigma-Aldrich (St. Louis, MO).
Virus and vectors
Stock virus of HIV strains 4-3 and AD8 grown in human
peripheral blood lymphocytes were kindly provided by
Tatsu Igarashi, Laboratory of Molecular Microbiology, NIH.
The HIV-l luciferase reporter vector pNL4-3.Luc.R-E-
(Connor et al., 1995; He et al., 1995) was obtained from
the NIAID AIDS Research and Reference Reagent Program
(http://www.aidsreagent.org). For expression of HIV-1 tat
and env, we used plasmid pNL4-3.dl1443, which was
derived from pNL4-3 by deleting 3.1 kb of gag sequences
between SphI and MscI sites (Felser et al., 1988). The
chimeric IIIB(JR-FL V3) envelope and the 92UG021.6
envelope genes were kindly provided by P. Bieniasz in
pNL4-3 vectors (Zhang et al., 2002), from which the 3.1-kb
SphI–MscI fragment was deleted. The HXB2-IIIB envelope
gene was kindly provided by Klaus Strebel at the NIAID,
NIH, and was transferred as an EcoRI–XhoI fragment to
pNL4-3.dl1443. Pseudotyped vector stocks were made by
co-transfecting HEK293 cells with the pNL4-3.Luc.R-E-
reporter vector (which encodes luciferase driven by an HIV
LTR and all HIV genes necessary for particle production
except envelope) along with an envelope protein expression
vector. Supernatants were collected 2 days later and passed
through 0.45-Am filters. Supernatants contained 3000–6000
cpm of reverse transcriptase (RT) activity/Al, but they varied
markedly in infectivity for U373 MAGI cells as measured
by luciferase activity 2 days after infection, presumably
reflecting different levels or fusion efficiencies of the
envelope proteins: for equal amounts of RT activity, the
VSV-G pseudotype stock was approximately 60 times more
infectious than the HIV strain 4-3 pseudotype, which in turn
was about twice as infectious as the amphotropic MLV
pseudotype. To partially compensate for these differences in
infectivity, we used 10 Al of VSV-G pseudotype virus stock
versus 50 Al of HIV envelope and amphotropic MLV
envelope pseudotype virus per well of a 24-well plate when
infecting U373-MAGI cells.
Confocal microscopy
Cells were grown in LabTek Chambered Coverglass
devices and examined with a Leica SP2-AOBS confocal
microscope with a 63 oil immersion NA 1.32 objective.
Detector slits were adjusted to minimize cross-talk between
the channels. DIC images were collected simultaneously
using a transmitted light detector. Images were processed
using Leica TCS-NT/SP software.Cell staining and flow cytometry
Cells (4  105) were incubated with oligonucleotides or
DEAE-dextran for 15 min on ice and washed in phosphate-
buffered saline (PBS) containing calcium and magnesium
(BioWhittaker, Walkersville, MD) plus 0.2% bovine serum
albumin. Alexa Flour 647-R-Phycoerythrin streptavidin
(Molecular Probes, Portland, OR) was used to detect biotin,
and allophycocyanin-labeled monoclonal antibody to
human CXCR4 (clone 12G5, cat # 555976, Pharmingen,
San Diego, CA) was used to detect CXCR4 co-receptor on
the cell surface. FITC-labeled cholera toxin B (cat # C1655,
Sigma-Aldrich) was used to detect the raft lipid GM1.
Stained cells were incubated on ice at 37 8C in a CO2
incubator or fixed with 1% paraformaldehyde as indicated.
Flow cytometry data were acquired on a FACSCalibur
(Becton Dickinson) and analyzed with CELLQUEST
software (Becton Dickinson, San Jose, CA). Fluorescein
was detected in channel FL1, Cy-5 in FL4, Alexa Fluor 647
in FL3, and allophycocyanin in FL4. Rainbow calibration
particles (Spherotech) were used according to the manu-
facturer’s instructions to determine equivalent number of
fluorescein molecules.
Cell culture and fusion assays
HEK293 cells from the American Type Culture Collec-
tion (Gaithersburg, MD) were transfected in 6-well culture
plates (Corning Life Sciences, Acton, MA) at approximately
50% confluence with 1–4 Ag of DNA and 2–8 Al of
lipofectamine 2000 (Invitrogen, Carlsbad, CA)/well in Opti-
Mem medium (Invitrogen) according to the manufacturer’s
instructions. One to three days later, 1–2  105 transfected
cells were cultured with an equal number of indicator cells
in 24-well culture dishes (Corning Life Sciences). Triplicate
co-cultures were set up for each transfected cell. The next
day, the supernatant was removed and the cells lysed by
addition of 0.25 ml lysis buffer (Promega, Madison, WI).
After gentle rocking at room temperature for approximately
10 min, the cells were frozen, thawed, and centrifuged in an
Ependorf centrifuge for 1–2 min at maximum speed.
Supernatant (20–25 Al) was assayed for luciferase activity
using a luminometer that reads light emitted following
injection of 100 Al of luciferase substrate reagent (Promega).
The same supernatant (5 Al) was assayed for beta-
galactosidase activity using Galactostar reagents as sug-
gested by the manufacturer (Applied Biosystems, Foster
City, CA). Data are displayed as mean of triplicate
cultures F standard deviation. For indicator cells, we used
1G5 Jurkat cells (Aguilar-Cordova et al., 1994),
CEM.NRK-CCR5-Luc cells (Spenlehauer et al., 2001;
Trkola et al., 1999), LuSIV cells (Roos et al., 2000),
U373-MAGI-CXCR4CEM cells (Vodicka et al., 1997), or
HeLa TZM-bl cells (Derdeyn et al., 2000; Plat et al., 1998;
Wei et al., 2002), all obtained from the NIAID AIDS
Research and Reference Reagent Program (http://www.
K.-S. Ahn et al. / Virology 330 (2004) 50–6160aidsreagent.org). These cells express CD4 as well as
CXCR4, CCR5, or both co-receptors, and Luc or LacZ
reporter genes under the control of HIV LTRs activated by
the HIV tat protein. Cholesterol-labeled oligonucleotides or
other substances tested for inhibitory effect were added at
the time of co-culture and maintained in the culture medium
until cell lysis 16–24 h later unless otherwise indicated.
HIV-1 virus binding assay and HIV-1 infection
HeLa-TZM-bl cells were detached from tissue culture
plates by incubating with phosphate-buffered saline lacking
divalent cations (PBS) plus 10 mM EDTA at 37 8C,
washed with PBS containing 1% fetal calf serum (wash
buffer), and resuspended in wash buffer at 2  107 cells/ml.
Twenty-five microliters of this cell suspension was incu-
bated with an equal volume of stock virus containing
approximately 104 HeLa-TZM-bl cell-infectious units of
HIV-1 strain 4-3 or approximately 103 HeLa-TZM cell-
infectious units of HIV-1 strain AD8. After 30 min at 37 8C,
one-tenth of the cells were plated in 0.5 ml Dulbecco’s
modified Eagle’s medium–10% fetal calf serum in 24-well
dishes for determination of infectious centers by staining
for beta-galactosidase 2 days later. The remaining cells
were washed twice by adding 1 ml of wash buffer,
centrifuging at 800  g for 3 min in an Ependorf
centrifuge, and carefully removing all but about 10 Al of
supernatant. Cells were lysed and p24 antigen measured
with a commercial kit (Zeptometrix, Buffalo, NY). Control
experiments showed the amount of cell-associated p24
antigen was the same after three washes as after two
washes. In experiments to test the effect of heparin or
oligonucleotide on virus binding and infectivity, cells and
virus were separately pre-incubated with heparin or
oligonucleotide for 30 min at 37 8C before mixing together.
In infectivity assays, the medium was changed 24 h after
infection and replaced with medium containing the same
concentration of heparin or oligonucleotide as used during
the cell–virus incubation.Acknowledgments
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